3 Drugs Stocks Moving The Industry Upward
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.
All three major indices are trading down today with the
Dow Jones Industrial Average
(
^DJI
) trading down 110 points (-0.6%) at 18,094 as of Wednesday, March 4, 2015, 11:55 AM ET. The NYSE advances/declines ratio sits at 978 issues advancing vs. 1,971 declining with 175 unchanged.
The Drugs industry currently sits up 0.7% versus the S&P 500, which is down 0.5%. Top gainers within the industry include
(
), up 8.7%,
(
), up 5.5%,
(
), up 5.2%,
(
), up 4.8% and
(
), up 3.1%. A company within the industry that fell today was
(
), up 0.6%.
TheStreet would like to highlight 3 stocks pushing the industry higher today:
3.
(
) is one of the companies pushing the Drugs industry higher today. As of noon trading, Celgene is up $1.47 (1.2%) to $119.94 on light volume. Thus far, 1.8 million shares of Celgene exchanged hands as compared to its average daily volume of 5.7 million shares. The stock has ranged in price between $116.53-$120.32 after having opened the day at $117.41 as compared to the previous trading day's close of $118.47.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally. Celgene has a market cap of $96.3 billion and is part of the health care sector. Shares are up 5.9% year-to-date as of the close of trading on Tuesday. Currently there are 16 analysts who rate Celgene a buy, no analysts rate it a sell, and 4 rate it a hold.
TheStreet Ratings rates
Celgene
as a
. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, robust revenue growth and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full
now.
2. As of noon trading,
(
) is up $2.71 (0.7%) to $415.50 on light volume. Thus far, 544,303 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $406.10-$415.79 after having opened the day at $410.95 as compared to the previous trading day's close of $412.79.
Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. Biogen Idec has a market cap of $97.6 billion and is part of the health care sector. Shares are up 21.6% year-to-date as of the close of trading on Tuesday. Currently there are 13 analysts who rate Biogen Idec a buy, no analysts rate it a sell, and 4 rate it a hold.
TheStreet Ratings rates
Biogen Idec
as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full
now.
1. As of noon trading,
(
) is up $0.69 (0.7%) to $103.48 on light volume. Thus far, 3.1 million shares of Gilead exchanged hands as compared to its average daily volume of 16.6 million shares. The stock has ranged in price between $101.66-$103.66 after having opened the day at $102.09 as compared to the previous trading day's close of $102.79.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $154.6 billion and is part of the health care sector. Shares are up 9.1% year-to-date as of the close of trading on Tuesday. Currently there are 15 analysts who rate Gilead a buy, 1 analyst rates it a sell, and 3 rate it a hold.
TheStreet Ratings rates
Gilead
as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, attractive valuation levels, expanding profit margins and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full
now.
If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
(
) while those bearish on the drugs industry could consider
ProShares UltraShort Nasdaq Biotech
(
).
null